Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

NCT02031419 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02031419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02031419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
December 18, 2013
Completion date
December 12, 2023
Enrollment
174 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large b-cell, diffuse